IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS

被引：0
|
作者：
Pierola, A. Alfonso [1 ]
Montalban-Bravo, G. [1 ]
Takahashi, K. [1 ]
Jabbour, E. J. [1 ]
Kadia, T. [1 ]
Ravandi, F. [1 ]
Cortes, J. [1 ]
DiNardo, C. [1 ]
Daver, N. [1 ]
Borthakur, G. [1 ]
Pemmaraju, N. [1 ]
Konopleva, M. [1 ]
Bueso-Ramos, C. [2 ]
Pierce, S. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Hematopathol, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P665
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [31] HYPOMETHYLATING AGENTS ARE EFFECTIVE IN SHRINKING SPLENOMEGALY IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): MAYO CLINIC EXPERIENCE
    Subari, S.
    Patnaik, M.
    Alfakara, D.
    Zblewski, D.
    Hook, C.
    Hashmi, S.
    Hogan, W.
    Litzow, M.
    Al-Kali, A.
    HAEMATOLOGICA, 2015, 100 : 489 - 489
  • [32] Venetoclax (VEN) Improves Response Rates but Not Survival in Patients with Chronic Myelomonocytic Leukemia ( CMML) Treated with Hypomethylating Agents (HMA): A Multicenter, Propensity Score Analysis
    Tremblay, Douglas
    Csizmar, Clifford M.
    DiNardo, Courtney D.
    Ball, Somedeb
    Rippel, Noa
    Hammond, Danielle E.
    Kadia, Tapan M.
    Ravandi, Farhad
    Chien, Kelly S.
    Van Hyfte, Grace
    Saliba, Antoine
    Mangaonkar, Abhishek A.
    Lasho, Terra L.
    Al-Kali, Aref
    Kremyanskaya, Marina
    Feld, Jonathan
    Silverman, Lewis R.
    Komrokji, Rami S.
    Mascarenhas, John
    Padron, Eric
    Garcia-Manero, Guillermo
    Sallman, David A.
    Patnaik, Mrinal M.
    Montalban-Bravo, Guillermo
    BLOOD, 2023, 142
  • [33] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [34] CLINICAL-RISK FACTORS THAT INFLUENCE AN OPTIMAL HYPOMETHYLATING AGENTS TREATMENT IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA
    Iastrebner, M.
    Lazzarino, C.
    Nucifora, E.
    Penchasky, D.
    Fernandez, I.
    Gusmao Moreno, B. G. M.
    Rivas, M. M.
    Espinosa, D.
    Abello Polo, V.
    Boada, M.
    Enrico, A.
    Araujo Schuster, S.
    Agra, M.
    Sarmiento, M.
    Flores, G.
    Alfonso, G.
    Crisp, R.
    Gusmao Moreno, B.
    Consortium, I.
    LEUKEMIA RESEARCH, 2017, 55 : S64 - S64
  • [35] RANDOMIZED PHASE 2 STUDY OF GUADECITABINE IN PATIENTS WITH HMA-NAIVE HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Savona, M. R.
    Garcia-Manero, G.
    Roboz, G. J.
    Walsh, K. J.
    Kropf, P. L.
    Issa, J. P.
    O'Connell, C. L.
    Tibes, R.
    Yee, K. W. L.
    Stock, W.
    Lunin, S.
    Berdeja, J. G.
    Naim, S.
    Hao, Y.
    Azab, M.
    Kantarjian, H.
    LEUKEMIA RESEARCH, 2017, 55 : S40 - S41
  • [36] An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups
    Montoro, Julia
    Pomares, Helena
    Merchan, Brayan
    Molero, Antonieta
    Saumell, Silvia
    Alonso, Esther
    Fernandez, Monica
    Gallur, Laura
    Grau, Javier
    Salamero, Olga
    Blanco, Adoracion
    Varela, Anna
    Roldan, Elisa
    Sureda, Anna
    Bosch, Francesc
    Sangerman, Montserrat Arnan
    Valcarcel, David
    BLOOD, 2017, 130
  • [37] Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)
    Radakovich, Nathan
    Sekeres, Mikkael A.
    Hilton, Cameron Beau
    Mukherjee, Sudipto
    Shreve, Jacob
    Rouphail, Yazan
    Shirley, Rachel
    Adema, Vera
    Awada, Hassan
    Advani, Anjali S.
    Kerr, Cassandra M.
    Nagata, Yasunobu
    Guan, Yihong
    Kuzmanovic, Teodora
    Hasipek, Metis
    Jha, Babal K.
    Maciejewski, Jaroslaw P.
    Nazha, Aziz
    BLOOD, 2019, 134
  • [38] Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
    Harel, Stephanie
    Cherait, Amina
    Berthon, Celine
    Willekens, Christophe
    Park, Sophie
    Rigal, Marthe
    Brechignac, Sabine
    Thepot, Sylvain
    Quesnel, Bruno
    Gardin, Claude
    Ades, Lionel
    Fenaux, Pierre
    Braun, Thorsten
    LEUKEMIA RESEARCH, 2015, 39 (05) : 501 - 504
  • [39] Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience
    Duque, Adolfo Diaz
    Cabrero, Monica
    Ravandi, Farhad
    Pemmaraju, Naveen
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Daver, Naval G.
    Jabbour, Elias
    Manero, Guillermo Garcia
    Sasaki, Koji
    BLOOD, 2014, 124 (21)
  • [40] Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Shan, Jianqin
    O'Brien, Susan
    Cortes, Jorge
    Ravandi, Farhad
    Issa, Jean-Pierre J.
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 585 - 586
12345